Phase III HLX02 Study Meets Primary End Point in Patients with HER2+ Breast Cancer

Henlius announced that their multicenter phase III study met its primary end point of best overall response rate at week 24.

Source: CancerNetwork - November 26, 2019 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news